Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-09

Clinical Trial Update: An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of Somatuline Depot (lanreotide) for carcinoid syndrome has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SOMATULINE DEPOT (LANREOTIDE ACETATE)

Snippet

Sponsor: Ipsen | Conditions: Carcinoid Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2016-02-09